Ahmedabad: City-based pharmaceutical major Zydus Cadila on Wednesday announced that it has reduced the price of Remdac to Rs 899 for a 100mg lyophilized injection. Remdac is a generic version of Gilead Sciences’ antiviral drug remdesivir, which is used in the treatment of Covid-19.
Zydus Cadila’s Remdac was priced at Rs 2,800 per 100 mg vial when launched in August last year. Back then, it was the most affordable among the available remdesivir versions in India.
According to the company, the move to further revise the prices will go a long way in helping patients during these critical times.
“Remdac has been one of the critical drugs in the disease management on Covid and we hope that this price cut will enable people from every strata of the society to access this critical drug,” said Sharvil Patel, managing director, Cadila Healthcare Limited, the flagship company of the Zydus Group.
In June 2020, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc. to manufacture and sell remdesivir, which has been issued an emergency use authorization by the US Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of Covid-19.